← Browse by Condition
Medical Condition

advanced solid tumors

Total Trials
41
Recruiting Now
41
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced solid tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced solid tumors Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumors?
ClinicalMetric currently tracks 41 actively recruiting clinical trials for advanced solid tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 41. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced solid tumors?
advanced solid tumors research spans Phase 1 (36 trials), Phase 2 (15 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced solid tumors clinical trial?
Eligibility criteria for advanced solid tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
36
Phase 2
15
Top Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 3 trials
Gilead Sciences 2 trials
Jiangsu HengRui Medicine Co., Ltd. 2 trials
Merck Sharp & Dohme LLC 2 trials
Revolution Medicines, Inc. 2 trials

Recruiting Clinical Trials

NCT06657222 Phase 1, Phase 2
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Enrollment
250 pts
Location
United States, Canad...
Sponsor
Gilead Sciences
View Trial →
NCT07779798 Phase 1
Recruiting
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
Enrollment
120 pts
Location
United States
Sponsor
Crossbow Therapeutics, Inc.
View Trial →
NCT06094556 Phase 1
Recruiting
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
Enrollment
240 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT06238401 Phase 1
Recruiting
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Enrollment
77 pts
Location
China
Sponsor
Hangzhou Adcoris Biopharmacy C...
View Trial →
NCT06555068 Phase 1, Phase 2
Recruiting
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
Enrollment
528 pts
Location
China
Sponsor
Jiangsu HengRui Medicine Co., ...
View Trial →
NCT06703177 Phase 1, Phase 2
Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Enrollment
876 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT06773091 Phase 1
Recruiting
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
Enrollment
76 pts
Location
China
Sponsor
Shanghai NK Cell Technology Co...
View Trial →
NCT07793942 Phase 2
Recruiting
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
Enrollment
480 pts
Location
United States, Canad...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT07397338 Phase 1, Phase 2
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Enrollment
370 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
View Trial →
NCT06990698 Phase 1
Recruiting
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
Enrollment
108 pts
Location
China
Sponsor
Zhuhai Fapon Biopharma Co., Lt...
View Trial →
NCT07750132 Phase 1
Recruiting
Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors
Enrollment
72 pts
Location
China
Sponsor
Beijing StarMab Biomed Technol...
View Trial →
NCT05620017 Phase 1
Recruiting
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Enrollment
182 pts
Location
China
Sponsor
Bio-Thera Solutions
View Trial →
NCT07046650 Phase 2
Recruiting
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
Enrollment
84 pts
Location
China
Sponsor
Sheng Zhang
View Trial →
NCT06694480 Phase 1
Recruiting
Study of FID-022 in Participants With Advanced Solid Tumors
Enrollment
24 pts
Location
United States
Sponsor
Fulgent Pharma LLC.
View Trial →
NCT07359066 Phase 1, Phase 2
Recruiting
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Enrollment
210 pts
Location
China
Sponsor
Shanghai SciBrunch Therapeutic...
View Trial →
NCT05867420 Phase 1, Phase 2
Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Enrollment
594 pts
Location
United States, China
Sponsor
AskGene Pharma, Inc.
View Trial →
NCT06739291 Phase 1
Recruiting
A Study of SIGX1094R in Patients With Advanced Solid Tumors
Enrollment
102 pts
Location
China
Sponsor
Signet Therapeutics
View Trial →
NCT06214143 Phase 1, Phase 2
Recruiting
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Enrollment
68 pts
Location
China
Sponsor
Shanghai Pharmaceuticals Holdi...
View Trial →
NCT07186452 Phase 1
Recruiting
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Enrollment
18 pts
Location
China
Sponsor
Hansoh BioMedical R&D Company
View Trial →
NCT06835569 Phase 1
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Enrollment
448 pts
Location
United States
Sponsor
Alterome Therapeutics, Inc.
View Trial →
NCT05944224 Phase 1, Phase 2
Recruiting
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
Enrollment
63 pts
Location
China
Sponsor
Shanghai Pharmaceuticals Holdi...
View Trial →
NCT06520488 Phase 1, Phase 2
Recruiting
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Enrollment
118 pts
Location
China
Sponsor
Jiangsu HengRui Medicine Co., ...
View Trial →
NCT06417554 Phase 1, Phase 2
Recruiting
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Enrollment
80 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
View Trial →
NCT07252414 Phase 1
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
Enrollment
180 pts
Location
United States, China
Sponsor
Changchun GeneScience Pharmace...
View Trial →
NCT06618651 Phase 1
Recruiting
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
Enrollment
162 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT06882135 Phase 1
Recruiting
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Enrollment
76 pts
Location
China
Sponsor
Wuhan Humanwell Innovative Dru...
View Trial →
NCT07161414 Phase 1
Recruiting
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
Enrollment
40 pts
Location
United States, South...
Sponsor
AstraZeneca
View Trial →
NCT07601334 Phase 1
Recruiting
Safety and Activity of HF50 in Patients With Advanced Solid Tumors
Enrollment
45 pts
Location
China
Sponsor
HighField Biopharmaceuticals C...
View Trial →
NCT05592626 Phase 1, Phase 2
Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Enrollment
366 pts
Location
United States, Canad...
Sponsor
Marengo Therapeutics, Inc.
View Trial →
NCT07266285 Phase 1
Recruiting
BTM-3566 in Advanced Solid Tumors
Enrollment
30 pts
Location
United States
Sponsor
Bantam Pharmaceuticals
View Trial →
NCT06993870 Phase 1
Recruiting
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Shenyang Sunshine Pharmaceutic...
View Trial →
NCT06736327 Phase 1
Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Enrollment
180 pts
Location
China
Sponsor
Sichuan Kelun-Biotech Biopharm...
View Trial →
NCT06040541 Phase 1
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Enrollment
604 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
View Trial →
NCT06299839 Phase 1
Recruiting
PAS-004 in Patients With Advanced Solid Tumors
Enrollment
83 pts
Location
United States, Bulga...
Sponsor
Pasithea Therapeutics Corp.
View Trial →
NCT06532565 Phase 1
Recruiting
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Enrollment
154 pts
Location
United States, Canad...
Sponsor
Gilead Sciences
View Trial →
NCT06760819 Phase 2
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Enrollment
111 pts
Location
United States, Austr...
Sponsor
Bayer
View Trial →
NCT07251166 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Enrollment
170 pts
Location
China
Sponsor
Changchun GeneScience Pharmace...
View Trial →
NCT07785609 Phase 2
Recruiting
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
Enrollment
200 pts
Location
United States, Hong ...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT07156253 Phase 1
Recruiting
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Enrollment
110 pts
Location
China
Sponsor
Hangzhou SynRx Therapeutics Bi...
View Trial →
NCT07067567 Phase 1
Recruiting
A Study of AK146D1 for Injection in Advanced Solid Tumors
Enrollment
200 pts
Location
China
Sponsor
Akeso
View Trial →
NCT06889675
Recruiting
First in Human Study of YB1-X7 Injection
Enrollment
48 pts
Location
China
Sponsor
Shaoxing Salvectors Biotechnol...
View Trial →

Related Conditions

nsclc (2) crc (2) non small cell lung cancer nsclc (2) colorectal cancer crc (2) nsclc non small cell lung cancer (2) hnscc (1) sclc (1) tnbc triple negative breast cancer (1) recurrent or progressive glioblastoma (1) relapse or refractory myeloid malignancies (1) advanced unresectable or metastatic breast cancer (1) malignant neoplam (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology